ResQ Pharma, Inc. was back in front of investors at the Chicago Capital Call: Biotech conference hosted today by Cooley LLP. Another great opportunity to showcase the hard work our team has put into bringing #LipidRescue to market in the near future. Thanks to Nader Elrashidy for organizing such a great event to collaborate and network among a diverse and highly-motivated group of people who all share one common goal: saving lives!
ResQ Pharma, Inc.’s Post
More Relevant Posts
-
Today marks the first day of trading in Trill Impact’s portfolio company Cinclus Pharma on Nasdaq Stockholm. The listing is an important milestone that enables continued development of the company’s drug candidate linaprazan glurate, which aims to improve the medical outcomes for patients suffering from severe stomach acid-related disorders worldwide. Nina Rawal, Partner at Trill Impact Advisory and Co-head of Trill Impact Ventures was present when the opening bell rang this morning. “It is of course very exciting to see Cinclus Pharma being listed on Nasdaq Stockholm today. To us, the fact that Cinclus Pharma has attracted investor interest in the current financial climate, is a great testament to the quality of the asset and the strong management team. When Trill Impact invested in Cinclus Pharma a couple of years back, we were confident that the company had the potential to become a global leader in the treatment of severe gastric acid-related disease. Since then, the company has reported strong Phase II data and is now ready to move into the final stage of clinical development". Read more about the #IPO here: https://lnkd.in/d7tvcBPC #impactinvesting #biotech #healthcare #lifescience #SDG3
To view or add a comment, sign in
-
-
Our thanks to Stephen West for that kind reflection on his Flint Digital experience. Roquefort Therapeutics plc, is a listed biotech company focused on developing first in class medicines in the high value and high growth oncology market. Using our Vega theme, Roquefort’s website is a great example of how a corporate website can be professional, easy to use and reliable, while meeting best-practice Investor Relations requirements for companies listed on the LSE Main Market. We are proud to contribute to Roquefort Therapeutics' mission by providing a digital solution that reflects their stature in the oncology sector and meets the high expectations of their investors and partners. Are you looking to amplify your company’s digital presence with a website that avoids CapEx but embodies professionalism, functionality, and compliance with investor relations standards? Flint Digital specialises in creating bespoke digital experiences that not only look exceptional but also deliver on strategic business objectives. Let's discuss how we can support your mission and transform your digital identity. Contact us today to start the conversation. #investorrelations #energyindustry #biotechnologyindustry #corporatewebsites
To view or add a comment, sign in
-
-
WSB Investor Call | June 21, 2022 (Preview) Here's a preview of the investor call with David Maris and Sarepta Therapeutics CEO Douglas S. Ingram. Whether you own $SRPT or thinking of getting long, you can't miss this discussion. "Our goal here is to delve deeper into the implications of the approval and understand Sarepta's longer term objectives." - David Maris "This is an enormous moment for the company." - Doug Ingram Access the entire Investor Call on $SRPT and don't miss Doug's incredible insights near the end on the importance of corporate culture in his organizations. Click the link in the comments sections to access. Fantastic discussion gentlemen! #InvestSmarter
To view or add a comment, sign in
-
📰 Weekly Healthcare & Life Sciences transactions selection: GREENPEAK Partners-backed Paratus (🇩🇪) secures majority ownership in DB Soft (🇪🇸). Resolve Stroke (🇫🇷) raises €2.2m with Quantonation and OVNI Capital. Broken String Biosciences (🇩🇪) closes $15M Series A Funding Round co-led by Illumina Ventures and Merieux Equity Partners. Pharmanovia (🇬🇧) acquire 11 central nervous system brands from Sanofi (🇫🇷). ReCode Therapeutics (🇺🇸) announced the closing of an extension to its Series B financing, raising an additional $50m with new investor Bioluminescence Ventures and Solasta Ventures. MCH Private Equity has invested in FARMALIDER GROUP (🇪🇸). REEV (techstars '23) (🇫🇷) raises €3m from Polytechnique Ventures, IRDI Capital Investissement, and Newfund. Search your next deal among #privateequity #investments and millions of company profiles on Tsylana app for #investmentbanking #corporatefinance and #capitalinvestissement professionals.
To view or add a comment, sign in
-
CEO and Founder of Genoplex.ai | Comms Committee @ ASGCT | Host of Rx for Biotech Podcast & TEDx Speaker
Check out this webinar with Chris Dokomajilar on January 16th to see what the year may look like for biopharma dealmaking in 2024! #venturecapital #biotech #biopharma #pharma #dealmaking #2024predictions
Join DealForma and Inpart for a look at how 2023 wrapped up and what is ahead for biopharma dealmaking in 2024. To kick-off a new year in partnering, Chris Dokomajilar, founder and CEO of DealForma, joins Inpart in this exclusive webinar. Reserve your free seat! https://lnkd.in/g7cTNFji
To view or add a comment, sign in
-
-
Cranmore Executive Search played a pivotal role in Horizon's rapid and successful expansion into the European market. "I highly recommend Cranmore," says Chris Serafino. "My contact, Chris Sannwald is a very effective partner and helps me not only find the right candidate and fit, but also is patient with me as my needs grow or change." Read the full case study below on how Cranmore's tailored approach to executive search empowered Horizon Therapeutics' European expansion and fuelled their remarkable success! 📈✨ #SuccessStories #ExecutiveSearch #EuropeanExpansion #HorizonTherapeutics
To view or add a comment, sign in
-
What do biotech investors look for when considering a deal? Strong leadership, strategic foresight, financial efficiency, and deep industry knowledge are all key deciding factors. Curious to learn more? Gain invaluable insights on M&A advisory and investor decision-making from Bracken Managing Partner, James Gilligan, in this blog post: https://lnkd.in/eMzHrtpx #LifeSci #Biopharma #Investing #DueDiligence #Bracken
To view or add a comment, sign in
-
BGPartner advises Novo Holdings, EQT, OrbiMed and SR One on $100 mio Series C financing of Asceneuron SA Swiss biotech company Asceneuron SA successfully closed a $100 mio oversubscribed Series C financing round. The financing round was led by Novo Holdings with new investment from EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One Capital Management, alongside participation from existing investors Merck Serono S.p.A., Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. The funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease. BGPartner advised lead investor Novo Holdings as well as the investors EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One, on all Swiss legal matters and the negotiations of this Series C financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate). More information can be found here: https://lnkd.in/d278vevG More information about our legal and negotiation expertise can be found here: https://lnkd.in/eFQjD5fw #Financing #swiss #Biotech #law #negotiation #Alzheimer
To view or add a comment, sign in
-
-
venBio Closes $528 Million Life Sciences Fund V Learn more & get our take 👇 https://lnkd.in/ghUkQKsh “With a highly concentrated portfolio and active involvement in each company, we are proud to have helped build companies that have achieved nine FDA drug approvals over the past six years, with many more generating promising clinical efficacy and safety data.” — Dr. Aaron Royston, M.D., Managing Partner at venBio “Our portfolio is directly impacting patient lives, and we could not have achieved this without the ongoing commitment from our limited partners. Fund V is structured to enable us to continue our proven approach of being highly selective in company building, while doubling down on winners around key inflection points, including in crossover rounds and at IPO.” — Dr. Corey Goodman, Managing Partner at venBio “In structuring Fund V, our primary goal was to maintain consistency in our strategy, core team and investment discipline, and we look forward to her continued contributions to the firm.” — Dr. Richard Gaster, M.D., Ph.D., Managing Partner at venBio #funding #lifesciences #SoHCNews
venBio Closes $528 Million Life Sciences Fund V
https://sliceofhealthcare.com
To view or add a comment, sign in
-
Bonum Therapeutics' John Mulligan, Ph.D. drops a gold nugget of wisdom in today's #BusinessOfBiotech for anyone who has to make executive decisions. In other words, that's just about everybody. When prioritizing tasks, you generally have three types. Low complexity/high value — these are rare. High complexity/low value — these are abundant. High complexity/high value — these are the Goldilocks tasks. I don't know about you, but I can get confused by those abundant high-complexity/low-value tasks. They're easy to spot but sneaky about hiding their payout value. I bet discerning the difference saves a ton of time and boosts productivity.
IL-2 Platform Profits With Bonum's Drs. John Mulligan And Neela Patel
bioprocessonline.com
To view or add a comment, sign in